High Cost Might Limit Access To Newer, Brand-Name PrEP Regimen, Researchers Say
Reuters Health: New brand-name HIV-prevention pill not worth the added cost: study
“A cheaper HIV prevention pill is going on sale soon in the U.S., but the price drop won’t help as many people if doctors instead prescribe a newer, more expensive brand-name drug, experts say. HIV pre-exposure prophylaxis (PrEP), a cocktail of drugs combined in a single pill taken once a day, can reduce the risk of HIV infections from sex or injected drug use by up to 99%, researchers note in the Annals of Internal Medicine. High costs, however, keep many patients who need PrEP from taking it…” (Rapaport, 3/9).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.